Relacorilant
Hypercortisolism from adrenal adenoma/hyperplasia - GRADIENT
Key Facts
About Corcept Therapeutics
Corcept Therapeutics has successfully transitioned from a research entity to a fully integrated commercial organization, anchored by its FDA-approved product Korlym® for hypercortisolism. Its core strategy leverages a proprietary platform of selective cortisol modulators, recently validated by the FDA approval of relacorilant (Lifyorli®) for platinum-resistant ovarian cancer. With over 30 ongoing studies across endocrinology, oncology, metabolism, and neurology, Corcept is pursuing a focused, independent path to expand the therapeutic reach of its unique mechanism.
View full company profileAbout Corcept Therapeutics
Corcept Therapeutics has successfully transitioned from a research entity to a fully integrated commercial organization, anchored by its FDA-approved product Korlym® for hypercortisolism. Its core strategy leverages a proprietary platform of selective cortisol modulators, recently validated by the FDA approval of relacorilant (Lifyorli®) for platinum-resistant ovarian cancer. With over 30 ongoing studies across endocrinology, oncology, metabolism, and neurology, Corcept is pursuing a focused, independent path to expand the therapeutic reach of its unique mechanism.
View full company profile